Rebooting the BTK Inhibitor Sequence in MCL

preview_player
Показать описание
Rebooting the BTK Inhibitor Sequence in MCL

  1. PeerView Oncology
  2. CME
  3. MOC
  4. NCPD
  5. CPE
  6. IPCE
Рекомендации по теме
Rebooting the BTK 0:59:49

Rebooting the BTK Inhibitor Sequence in MCL

What are BTK 0:22:57

What are BTK Inhibitors and Why Are They Different? From the Spring 2023 Education Summit

Novel BTK Inhibitors: 1:00:33

Novel BTK Inhibitors: Overcoming Intolerance, Resistance, and Other Challenges in B-Cell Cancers

BTK inhibitor-associated adverse 0:02:18

BTK inhibitor-associated adverse events in patients with CLL

Safety and Efficacy 0:05:11

Safety and Efficacy of BTK Inhibitors in R/R MCL

Targeting BTK in 0:03:53

Targeting BTK in B-Cell Malignancies

Comparison of the 0:03:42

Comparison of the different BTK inhibitors available & under investigation in frontline and R/R ...

Highlights From Bruton’s 1:13:43

Highlights From Bruton’s Tyrosine Kinase Inhibitors

2022 IWMF Ed 0:57:33

2022 IWMF Ed Forum-Everything You Want to Know About BTK Inhibitors, Do's and Don'ts

The value of 0:02:31

The value of BTK inhibitors in CLL & the future of acalabrutinib in this disease

New Rules for 1:27:57

New Rules for BTK Inhibitors in CLL

BTKI inhibitors in 0:01:33

BTKI inhibitors in the treatment of B-cell lymphoma - Introduction

Outcomes of CLL 0:01:19

Outcomes of CLL patients following treatment with a covalent BTK and BCL2 inhibitor

The sequencing of 0:22:47

The sequencing of novel agents: Does it matter?

Inside the Issue 1:03:39

Inside the Issue — Optimizing the Management of Adverse Events Associated with BTK Inhibitors

Everything You Wanted 0:57:33

Everything You Wanted To Know About BTK inhibitors.

PI3 Kinase Inhibitors 0:07:21

PI3 Kinase Inhibitors for Relapsed/Refractory CLL

Acalabrutinib & Zanubrutinib 0:04:40

Acalabrutinib & Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma - Blood Cancers Librar...

Taking the Leap 1:14:44

Taking the Leap With Innovative Strategies in MCL

CLL: Update on 0:20:23

CLL: Update on approved TKIs and their use in clinical practice

Role of PI3K 0:17:28

Role of PI3K inhibitors in clinical practice: Uses and pitfalls

CLL/SLL Overview | 1:01:42

CLL/SLL Overview | LRF Ed Forum Series

Ibrutinib resistance: Is 0:23:08

Ibrutinib resistance: Is it predictable? What to do?

How and when 0:08:28

How and when to treat patients with refractory or progressive WM